Literature DB >> 7958669

Glutamine dipeptide-supplemented parenteral nutrition maintains intestinal function in the critically ill.

H Tremel1, B Kienle, L S Weilemann, P Stehle, P Fürst.   

Abstract

BACKGROUND/AIMS: Long-term total parenteral nutrition is accompanied with mucosal atrophy and subsequent malabsorption syndrome. Current information attests the important role of glutamine in maintaining intestinal structure and function. The aim of this study was to investigate the effect of glutamine dipeptide supplementation on small intestinal absorption capacity during critical illness.
METHODS: Twelve intensive care unit patients were uniformly randomized to receive isonitrogenous (0.26 g nitrogen.kg-1.day-1) and isoenergetic (155 kJ.kg-1.day-1) parenteral nutrition over 9 days. The control group received a conventional amino acid solution (1.5 g amino acids.kg-1.day-1), and the test group received a complete amino acid solution containing the dipeptide L-alanyl-L-glutamine (20 g/L). On days 8 and 9, a modified D-xylose test was performed.
RESULTS: Excretion of D-xylose during the 5-hour test period was 7.4 +/- 1.1 g (test) vs. 3.8 +/- 0.9 g (control) (P < 0.05). The 2-hour serum D-xylose concentration was 38.7 +/- 3.0 (test) vs. 27.8 +/- 2.9 mg/100 mL (control) (P < 0.05). Kinetic evaluation showed higher maximum D-xylose blood concentration and higher values for the area under the curve with the peptide.
CONCLUSIONS: The results strongly suggest that glutamine dipeptide-containing total parenteral nutrition prevents intestinal atrophy and increased permeability associated with glutamine-free parenteral nutrition.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7958669     DOI: 10.1016/0016-5085(94)90797-8

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  24 in total

Review 1.  Nutritional papers in ICU patients: what lies between the lines?

Authors:  Jean-Charles Preiser; René Chioléro; Jan Wernerman
Journal:  Intensive Care Med       Date:  2002-12-21       Impact factor: 17.440

2.  Reduced stress tolerance of glutamine-deprived human monocytic cells is associated with selective down-regulation of Hsp70 by decreased mRNA stability.

Authors:  Maja Munk Eliasen; Marianne Brabec; Christopher Gerner; Jürgen Pollheimer; Herbert Auer; Maria Zellner; Gertrude Weingartmann; Fritz Garo; Erich Roth; Rudolf Oehler
Journal:  J Mol Med (Berl)       Date:  2005-11-25       Impact factor: 4.599

3.  EGF receptor plays a role in the mechanism of glutamine-mediated prevention of alcohol-induced gut barrier dysfunction and liver injury.

Authors:  Avtar S Meena; Pradeep K Shukla; Parimal Sheth; RadhaKrishna Rao
Journal:  J Nutr Biochem       Date:  2018-11-06       Impact factor: 6.048

Review 4.  [Immunonutrition in intensive care medicine].

Authors:  A Weimann
Journal:  Med Klin Intensivmed Notfmed       Date:  2013-01-26       Impact factor: 0.840

5.  Effects of glutamine supplements and radiochemotherapy on systemic immune and gut barrier function in patients with advanced esophageal cancer.

Authors:  S Yoshida; M Matsui; Y Shirouzu; H Fujita; H Yamana; K Shirouzu
Journal:  Ann Surg       Date:  1998-04       Impact factor: 12.969

6.  Clostridium difficile toxin A induces intestinal epithelial cell apoptosis and damage: role of Gln and Ala-Gln in toxin A effects.

Authors:  Gerly A C Brito; Benedito Carneiro-Filho; Reinaldo B Oriá; Raul V Destura; Aldo A M Lima; Richard L Guerrant
Journal:  Dig Dis Sci       Date:  2005-07       Impact factor: 3.199

7.  The protective effects of glutamine on radiation-induced diarrhea.

Authors:  Eda Kucuktulu; Ali Guner; Izzettin Kahraman; Murat Topbas; Uzer Kucuktulu
Journal:  Support Care Cancer       Date:  2012-10-14       Impact factor: 3.603

8.  Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects.

Authors:  Jerry R Greenfield; I Sadaf Farooqi; Julia M Keogh; Elana Henning; Abdella M Habib; Anthea Blackwood; Frank Reimann; Jens J Holst; Fiona M Gribble
Journal:  Am J Clin Nutr       Date:  2008-12-03       Impact factor: 7.045

9.  Treatment with glutamine is associated with down-regulation of Toll-like receptor-4 and myeloid differentiation factor 88 expression and decrease in intestinal mucosal injury caused by lipopolysaccharide endotoxaemia in a rat.

Authors:  A Kessel; E Toubi; E Pavlotzky; J Mogilner; A G Coran; M Lurie; R Karry; I Sukhotnik
Journal:  Clin Exp Immunol       Date:  2007-12-06       Impact factor: 4.330

10.  Improving the ORS: does glutamine have a role?

Authors:  Pradip K Bardhan
Journal:  J Health Popul Nutr       Date:  2007-09       Impact factor: 2.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.